Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: A worldwide developer, manufacturer, and marketer of minimally invasive medical devices across interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology, and neuromodulation.
Key Financial Metrics
| Metric (in millions) | Q3 2005 | Q3 2004 | 9 Months 2005 | 9 Months 2004 |
|---|---|---|---|---|
| Net Sales | $1,511 | $1,482 | $4,743 | $4,024 |
| Gross Profit | $1,168 | $1,173 | $3,699 | $3,060 |
| Gross Margin % | 77.3% | 79.1% | 78.0% | 76.0% |
| Operating Income (Loss) | $(336) | $358 | $503 | $1,070 |
| Net Income (Loss) | $(269) | $258 | $294 | $765 |
| Diluted EPS | $(0.33) | $0.30 | $0.35 | $0.89 |
| Cash from Operations (9mo) | $393 (vs $1,147 prior year) | |||
| Total Debt (Gross) | $2,514 (Sep 30, 2005) | |||
| Cash & Equivalents | $745 (Sep 30, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2% in Q3 and 18% for the nine months ended September 30, 2005. International sales grew 16% in Q3 and 19% for the nine-month period, driven by the TAXUS stent system. U.S. sales declined 5% in Q3 due to competitive pressures on the TAXUS Express 2 system but grew 17% for the nine-month period.
- Profitability Impact: The company reported a net loss of $269 million in Q3 2005 compared to net income of $258 million in Q3 2004. This reversal was primarily due to a $780 million pre-tax litigation-related charge associated with a settlement with Medinol Ltd. ($750 million cash payment plus cancellation of equity investment).
- Acquisitions: The company completed four acquisitions in 2005 (Advanced Stent Technologies, TriVascular, CryoVascular, and Rubicon Medical), resulting in $276 million in purchased research and development expenses for the nine-month period.
- Debt Structure: Gross debt increased to $2,514 million from $2,367 million at year-end 2004, largely to fund the Medinol settlement, share repurchases, and acquisitions. Net debt increased to $1,597 million.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue investing in sales forces and R&D. The company anticipates launching the TAXUS Liberté stent in the U.S. in the second half of 2006 and in Japan in the first half of 2007. The worldwide coronary stent market is estimated at $5.8 billion for 2005.
- Legal Risks: Significant ongoing intellectual property litigation with Johnson & Johnson (Cordis) and Medtronic regarding stent patents. While the Medinol litigation was settled, other cases remain pending with potential for material damages or injunctive relief.
- Regulatory Risks: The company has received FDA warning letters regarding global quality-control systems and an auditory product line. Resolution may require significant resources and could impact operations.
- Market Risks: Competitive pressures in the drug-eluting stent market, potential entry of new competitors in the U.S. by 2007, and foreign currency fluctuations affecting international margins.
- Contingent Consideration: Estimated maximum potential future contingent consideration for business combinations is approximately $4.5 billion, dependent on regulatory and performance milestones.
Investor Verification Checklist
- Medinol Settlement Impact: Verify the full cash outflow ($750 million) and the write-off of the equity investment included in the Q3 charge.
- TAXUS Stent Performance: Monitor the divergence between U.S. sales (declining in Q3 due to competition) and international sales (growing due to conversion rates from bare-metal to drug-eluting stents).
- Patent Litigation Status: Track the outcomes of pending jury trials with Johnson & Johnson and Medtronic, as damages or injunctions could materially affect future revenue.
- Regulatory Compliance: Confirm the status of FDA warning letter resolutions and any potential impact on manufacturing or product approvals.
- Debt Refinancing: Assess the company's plan to issue up to $750 million in long-term debt in Q4 2005 to refinance short-term commercial paper.